IMPACT OF GINGER SUPPLEMENTATION ON BLOOD PRESSURE AND GLUCOSE LEVELS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND
11Ibn Sina University of Medical and Pharmaceutical Sciences, Baghdad, Iraq.
Georgian Medical News
|March 10, 2026
Summary
Ginger supplementation significantly reduced inflammatory markers, improved lipid profiles, and enhanced glycemic control in patients with type 2 diabetes mellitus and cardiovascular disease. This natural intervention shows promise for managing cardiometabolic risk.
Area of Science:
- Cardiovascular Medicine
- Endocrinology
- Nutritional Science
Background:
- Chronic inflammation links type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD), contributing to insulin resistance and endothelial dysfunction.
- Ginger (Zingiber officinale) possesses anti-inflammatory and antioxidant properties that may positively impact cardiometabolic parameters.
Purpose of the Study:
- To investigate the effects of ginger supplementation on blood pressure, glucose levels, and inflammatory markers in patients with CVD and T2DM.
- To evaluate ginger's potential as an adjunctive therapy for cardiometabolic risk management.
Main Methods:
- A prospective, before-after interventional study with a control group involving 80 participants (27-44 years) with dyslipidemia, hyperglycemia, and hypertension.
- Participants received ginger infusion twice daily for 4 months; measurements included lipid profiles, fasting glucose, and inflammatory markers (hs-CRP, IL-6, PCT).
- Data analyzed using paired t-tests with significance set at p<0.05.
Main Results:
- Significant reductions observed in hs-CRP (20.5%) and IL-6 (25.2%) levels.
- Improvements in lipid profiles: LDL-C (-6.7%), VLDL-C (-17.9%), total cholesterol (-18.6%), and triglycerides (-13.6%).
- Significant decrease in fasting glucose levels; PCT levels remained unchanged.
Conclusions:
- Ginger supplementation effectively reduces inflammatory markers, improves lipid profiles, and enhances glycemic control in individuals with T2DM and CVD.
- Ginger can be considered an adjunctive treatment for managing cardiometabolic risk.
- Further large-scale studies are warranted to confirm these findings.
Related Concept Videos
01:22Diabetes Mellitus: Type 2 and Gestational
5.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.3K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
783
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
783
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
722
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
722
01:22Diabetes Mellitus: Overview and Type I Subtype
5.7K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.7K
01:15Diabetes: Management and Pharmacotherapy
1.2K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.2K
01:15Diabetes: Symptoms, Diagnosis, and Complications
2.6K
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
2.6K